PRMT4 blocks myeloid differentiation by assembling a Methyl-RUNX1-dependent repressor complex

Ly P. Vu; Fabiana Perna; Lan Wang; Francesca Voza; Maria E. Figueroa; Paul Tempst; Hediye Erdjument-Bromage; Rui Gao; Sisi Chen; Elisabeth Paietta; Tony Deblasio; Ari Melnick; Yan Liu; Xinyang Zhao; Stephen D. Nimer

doi:10.1016/j.celrep.2013.11.025

PRMT4 blocks myeloid differentiation by assembling a Methyl-RUNX1-dependent repressor complex

Ly P. Vu, Fabiana Perna, Lan Wang, Francesca Voza, Maria E. Figueroa, Paul Tempst, Hediye Erdjument-Bromage, Rui Gao, Sisi Chen, Elisabeth Paietta, Tony Deblasio, Ari Melnick, Yan Liu, Xinyang Zhao^*, Stephen D. Nimer

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

Defining the role of epigenetic regulators in hematopoiesis has become critically important, because recurrent mutations or aberrant expression of these genes has been identified in both myeloid and lymphoid hematological malignancies. We found that PRMT4, a type I arginine methyltransferase whose function in normal and malignant hematopoiesis is unknown, is overexpressed in acute myelogenous leukemia patient samples. Overexpression of PRMT4 blocks the myeloid differentiation of human stem/progenitor cells (HSPCs), whereas its knockdown is sufficient to induce myeloid differentiation of HSPCs. We demonstrated that PRMT4 represses the expression of miR-223 in HSPCs via the methylation of RUNX1, which triggers the assembly of a multiprotein repressor complex that includes DPF2. As part of the feedback loop, PRMT4 expression is repressed posttranscriptionally by miR-223. Depletion of PRMT4 results in differentiation of myeloid leukemia cells invitro and their decreased proliferation invivo. Thus, targeting PRMT4 holds potential as a novel therapy for acute myelogenous leukemia.

Original language	English (US)
Pages (from-to)	1625-1638
Number of pages	14
Journal	Cell reports
Volume	5
Issue number	6
DOIs	https://doi.org/10.1016/j.celrep.2013.11.025
State	Published - Dec 26 2013

Funding

We thank Michael Kharas, Minkui Luo, Ross Levine, and the members of the Nimer laboratory for providing thoughtful suggestions and comments. We thank the MSKCC Flow Cytometry core facility for their assistance and the Eastern Cooperative Oncology Group (ECOG) bank for making their database of AML patient samples available. The mass spectrometry work was supported by NCI Cancer Center support grant P30 CA08748 to Microchemistry and Proteomics Core Laboratory, MSKCC. We would like to thank Elizabeth Chang for help with mass spectrometry sample preparation. This study was funded by a grant from the National Institutes of Health (R01CA166835) and by the American Society of Hematology Scholar Award (to F.P.).

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.celrep.2013.11.025

Cite this

@article{dbcffe2680c64900b01632361959011d,

title = "PRMT4 blocks myeloid differentiation by assembling a Methyl-RUNX1-dependent repressor complex",

abstract = "Defining the role of epigenetic regulators in hematopoiesis has become critically important, because recurrent mutations or aberrant expression of these genes has been identified in both myeloid and lymphoid hematological malignancies. We found that PRMT4, a type I arginine methyltransferase whose function in normal and malignant hematopoiesis is unknown, is overexpressed in acute myelogenous leukemia patient samples. Overexpression of PRMT4 blocks the myeloid differentiation of human stem/progenitor cells (HSPCs), whereas its knockdown is sufficient to induce myeloid differentiation of HSPCs. We demonstrated that PRMT4 represses the expression of miR-223 in HSPCs via the methylation of RUNX1, which triggers the assembly of a multiprotein repressor complex that includes DPF2. As part of the feedback loop, PRMT4 expression is repressed posttranscriptionally by miR-223. Depletion of PRMT4 results in differentiation of myeloid leukemia cells invitro and their decreased proliferation invivo. Thus, targeting PRMT4 holds potential as a novel therapy for acute myelogenous leukemia.",

author = "Vu, \{Ly P.\} and Fabiana Perna and Lan Wang and Francesca Voza and Figueroa, \{Maria E.\} and Paul Tempst and Hediye Erdjument-Bromage and Rui Gao and Sisi Chen and Elisabeth Paietta and Tony Deblasio and Ari Melnick and Yan Liu and Xinyang Zhao and Nimer, \{Stephen D.\}",

note = "Funding Information: We thank Michael Kharas, Minkui Luo, Ross Levine, and the members of the Nimer laboratory for providing thoughtful suggestions and comments. We thank the MSKCC Flow Cytometry core facility for their assistance and the Eastern Cooperative Oncology Group (ECOG) bank for making their database of AML patient samples available. The mass spectrometry work was supported by NCI Cancer Center support grant P30 CA08748 to Microchemistry and Proteomics Core Laboratory, MSKCC. We would like to thank Elizabeth Chang for help with mass spectrometry sample preparation. This study was funded by a grant from the National Institutes of Health (R01CA166835) and by the American Society of Hematology Scholar Award (to F.P.). ",

year = "2013",

month = dec,

day = "26",

doi = "10.1016/j.celrep.2013.11.025",

language = "English (US)",

volume = "5",

pages = "1625--1638",

journal = "Cell reports",

issn = "2211-1247",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - PRMT4 blocks myeloid differentiation by assembling a Methyl-RUNX1-dependent repressor complex

AU - Vu, Ly P.

AU - Perna, Fabiana

AU - Wang, Lan

AU - Voza, Francesca

AU - Figueroa, Maria E.

AU - Tempst, Paul

AU - Erdjument-Bromage, Hediye

AU - Gao, Rui

AU - Chen, Sisi

AU - Paietta, Elisabeth

AU - Deblasio, Tony

AU - Melnick, Ari

AU - Liu, Yan

AU - Zhao, Xinyang

AU - Nimer, Stephen D.

N1 - Funding Information: We thank Michael Kharas, Minkui Luo, Ross Levine, and the members of the Nimer laboratory for providing thoughtful suggestions and comments. We thank the MSKCC Flow Cytometry core facility for their assistance and the Eastern Cooperative Oncology Group (ECOG) bank for making their database of AML patient samples available. The mass spectrometry work was supported by NCI Cancer Center support grant P30 CA08748 to Microchemistry and Proteomics Core Laboratory, MSKCC. We would like to thank Elizabeth Chang for help with mass spectrometry sample preparation. This study was funded by a grant from the National Institutes of Health (R01CA166835) and by the American Society of Hematology Scholar Award (to F.P.).

PY - 2013/12/26

Y1 - 2013/12/26

N2 - Defining the role of epigenetic regulators in hematopoiesis has become critically important, because recurrent mutations or aberrant expression of these genes has been identified in both myeloid and lymphoid hematological malignancies. We found that PRMT4, a type I arginine methyltransferase whose function in normal and malignant hematopoiesis is unknown, is overexpressed in acute myelogenous leukemia patient samples. Overexpression of PRMT4 blocks the myeloid differentiation of human stem/progenitor cells (HSPCs), whereas its knockdown is sufficient to induce myeloid differentiation of HSPCs. We demonstrated that PRMT4 represses the expression of miR-223 in HSPCs via the methylation of RUNX1, which triggers the assembly of a multiprotein repressor complex that includes DPF2. As part of the feedback loop, PRMT4 expression is repressed posttranscriptionally by miR-223. Depletion of PRMT4 results in differentiation of myeloid leukemia cells invitro and their decreased proliferation invivo. Thus, targeting PRMT4 holds potential as a novel therapy for acute myelogenous leukemia.

AB - Defining the role of epigenetic regulators in hematopoiesis has become critically important, because recurrent mutations or aberrant expression of these genes has been identified in both myeloid and lymphoid hematological malignancies. We found that PRMT4, a type I arginine methyltransferase whose function in normal and malignant hematopoiesis is unknown, is overexpressed in acute myelogenous leukemia patient samples. Overexpression of PRMT4 blocks the myeloid differentiation of human stem/progenitor cells (HSPCs), whereas its knockdown is sufficient to induce myeloid differentiation of HSPCs. We demonstrated that PRMT4 represses the expression of miR-223 in HSPCs via the methylation of RUNX1, which triggers the assembly of a multiprotein repressor complex that includes DPF2. As part of the feedback loop, PRMT4 expression is repressed posttranscriptionally by miR-223. Depletion of PRMT4 results in differentiation of myeloid leukemia cells invitro and their decreased proliferation invivo. Thus, targeting PRMT4 holds potential as a novel therapy for acute myelogenous leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84891008290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891008290&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2013.11.025

DO - 10.1016/j.celrep.2013.11.025

M3 - Article

C2 - 24332853

AN - SCOPUS:84891008290

SN - 2211-1247

VL - 5

SP - 1625

EP - 1638

JO - Cell reports

JF - Cell reports

IS - 6

ER -

PRMT4 blocks myeloid differentiation by assembling a Methyl-RUNX1-dependent repressor complex

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this